Overture

Overture Life is a clinical-stage biotechnology company automating assisted reproductive technology (ART) to improve IVF pregnancy outcomes and expand access to fertility care worldwide. The company develops robotic and AI-driven systems that standardize and automate the most complex embryology lab procedures — including egg fertilization (ICSI), embryo culture, and embryo selection — reducing variability, improving clinical outcomes, and enabling fertility clinics to scale operations at lower cost. Overture's technology is designed to extend treatment access to satellite clinics and remote locations. The company is headquartered in Madrid, Spain, with a U.S. operations hub in Dallas, Texas, and is backed by investors including Khosla Ventures, Felicis Ventures, and Octopus Ventures.